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Abstract
Purpose It is advantageous to individualize high-dose
methotrexate (HDMTX) to maintain adequate exposure
while minimizing toxicities. Previously, we accomplished
this through within-course dose adjustments.
Methods In this study, we evaluated a strategy to indi-
vidualize HDMTX based on clearance of each individual’s
previous course of HDMTX in 485 patients with newly
diagnosed acute lymphoblastic leukemia. Doses were
individualized to achieve a steady-state plasma concentra-
tion (Cpss) of 33 or 65 lM (approximately 2.5 or 5 g/m2/
day) for low- and standard-/high-risk patients, respectively.
Results Individualized doses resulted in 70 and 63 % of
courses being within 20 % of the targeted Cpss in the low-
and standard-/high-risk arms, respectively, compared to
60 % (p \ 0.001) and 61 % (p = 0.43) with convention-
ally dosed therapy. Only 1.3 % of the individualized
courses in the standard-/high-risk arm had a Cpss greater
than 50 % above the target compared to 7.3 % (p \ 0.001)
in conventionally dosed therapy. We observed a low rate
(8.5 % of courses) of grade 3–4 toxicities. The odds of
gastrointestinal toxicity were related to methotrexate
plasma concentrations in both the low (p = 0.021)- and
standard-/high-risk groups (p = 0.003).
Conclusions Individualizing HDMTX based on the
clearance from the prior course resulted in fewer extreme
Cpss values and less delayed excretion compared to con-
ventional dosing.
Keywords Methotrexate Acute lymphoblastic leukemia 
Pharmacokinetics  Individualized therapy
Introduction
Improvements in cure rates for childhood acute lympho-
blastic leukemia (ALL) are due partly to the use of risk-
directed chemotherapy [1–5]. One important element of
chemotherapy is high-dose methotrexate (HDMTX) (doses
C1 g/m2) with leucovorin rescue [3, 6–9]. High doses of
methotrexate (5 g/m2) improve the outcome of patients
with T-lineage ALL, consistent with the fact that T-lineage
blasts accumulate less methotrexate polyglutamates than
blasts of B-lineage ALL, thereby requiring higher serum
concentrations to achieve the same cytotoxic effect [6, 10–
12]. In addition, methotrexate dosages higher than 1 g/m2
are beneficial for patients with B-lineage ALL [13–16].
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However, HDMTX has been associated with potentially
severe toxicities, [17–20] although the introduction of
pretreatment prehydration, urinary alkalinization, routine
monitoring of serum methotrexate concentrations, and the
incorporation of leucovorin rescue has decreased their
incidence [21–25]. High plasma methotrexate concentra-
tions are also associated with increased toxicity which may
delay subsequent courses of chemotherapy [22, 26, 27].
Therefore, it is desirable to maintain plasma concentrations
within the putative cytotoxic range for leukemic blasts [28]
and below those associated with significant toxicity. We
previously conducted a prospective randomized trial in
children with ALL which demonstrated that when HDMTX
doses were adjusted during the 24-h drug infusion to
achieve desired plasma exposure levels, relapse rates were
lower compared to conventional fixed doses of metho-
trexate based on body surface area [13]. Another study in
patients with relapsed ALL showed that individualizing
doses decreased inter-patient variability and avoided
potentially toxic methotrexate concentrations [29].
However, adjusting doses of HDMTX during an infu-
sion requires extremely fast turn-around time for analysis
of plasma methotrexate concentrations, estimating phar-
macokinetic parameters, and implementing adjusted doses.
Therefore, the objectives of this follow-up study were to
evaluate the feasibility of an approach that individualized
HDMTX dosage based on the pharmacokinetics of each
individual patient’s previous course of methotrexate, with
14 or more days between each course and to assess the
acute toxicities associated with HDMTX.
Patients and methods
Between June 2000 and October 2007, 501 patients were
enrolled on St. Jude Total Therapy Study XV for ALL [1].
Three patients were subsequently excluded based on a
revised diagnosis of myeloid leukemia, and two patients
did not receive HDMTX during consolidation therapy. In
addition, for this analysis, 12 patients with Down syndrome
were excluded because they received lower doses of
methotrexate (500 mg/m2) that were not individualized
based on pharmacokinetics. During this front-line study of
childhood ALL, patients were randomly assigned to
receive initial treatment (window) with HDMTX (1 g/m2)
over a period of 4 or 24 h [30]. Four days later, remission-
induction therapy was begun with prednisone, vincristine,
daunorubicin, asparaginase, cyclophosphamide, mercapto-
purine and cytarabine. Risk classification was based on
presenting characteristics and treatment response to
remission-induction therapy, and patients were assigned to
the low-, standard- or high-risk categories [1]. Central
nervous system-directed therapy with triple intrathecal
therapy was given based on the patient’s central nervous
system status [1].
The 6-week induction period was followed by consoli-
dation, consisting of four courses of HDMTX given every
other week together with triple intrathecal therapy with
methotrexate, hydrocortisone and cytarabine on the day of
HDMTX and daily oral mercaptopurine at 50 mg/m2/day at
bedtime for the 8 weeks of consolidation. Serum chemis-
tries were required to be within normal limits prior to
receipt of HDMTX. Methotrexate doses were individual-
ized using the pharmacokinetic parameters estimated from
the individual’s previous course of HDMTX. If the patient
had not received HDMTX as part of window therapy, then
their first course of HDMTX in consolidation was a fixed
dose of 2.5 mg/m2 (low-risk arm) or 5 mg/m2 (standard-/
high-risk arm) infused over 24 h. Patients on the low-risk
treatment arm had doses individualized to achieve a steady-
state plasma concentration (Cpss) of 33 lM (the average
Cpss expected for patients receiving 2.5 g/m2/24 h based
on extensive prior pharmacokinetic estimates in children
with ALL) [13]. Those on the standard-/high-risk arm were
individualized to a Cpss of 65 lM (the average Cpss
expected for patients receiving 5 g/m2/24 h, based on prior
pharmacokinetic estimates) [13]. Patients received prehy-
dration containing sodium bicarbonate starting the evening
prior (at 100 or 125 mL/m2/h for low risk or standard/high
risk, respectively). In some cases, prehydration was
administered for a minimum of 2 h prior at 200 mL/m2/h
with a sodium bicarbonate bolus. This occurred in exten-
uating circumstances such as when patients were not able
to arrive in our clinic the evening prior to treatment. The
HDMTX was not started until the urine pH was C6.5.
Intravenous fluids continued until at least 42 h after the
start of methotrexate. HDMTX was given as a 10 %
loading dose over 1 h, with the remaining 90 % adminis-
tered over 23 h. Urine pH was monitored with each void,
and an IV sodium bicarbonate bolus was given if the urine
pH was B6 [22].
All patients had methotrexate concentrations measured
by fluorescence polarization immunoassay (TDx/TDxFLx
Systems, Abbot Laboratories, Abbot Park, IL, USA) prior
to the dose and at 6, 23 and 42 h from the infusion start.
The lower limit of quantification of the assay was 0.03 lM.
Leucovorin dosing
Leucovorin rescue was started at 42 h from the beginning
of the HDMTX infusion (Supplemental Table 1). Those on
the low-risk arm received 10 mg/m2 of leucovorin every
6 h for 5 doses and those on the standard-/high-risk arm
received 15 mg/m2 of leucovorin every 6 h for 5 doses.
Leucovorin doses were increased for patients with
delayed excretion of methotrexate, defined as methotrexate
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concentrations[1 lM at 42 h (Supplemental Table 1). For
those with delayed excretion, plasma methotrexate con-
centrations were monitored, and leucovorin was continued
until plasma methotrexate concentrations were \0.1 lM.
Patients with changes to their clinical status (e.g., an
increase in serum creatinine; early mucositis; evidence
of pleural effusions or ascites; significantly delayed
methotrexate excretion) were followed until they achieved
an undetectable plasma methotrexate concentration
(\0.03 lM).
Pharmacokinetic modeling
Methotrexate pharmacokinetic parameters were estimated
by fitting a two-compartment model [13, 31–33] to each
individual’s data set using the a posteriori probability
estimation method implemented in ADAPT II [34].
Extensive prior studies established the prior distribution of
the methotrexate pharmacokinetic parameters and allowed
the implementation of our Bayesian approach using rela-
tively sparse sampling (3–4 samples per course) in this and
our prior studies [13]. The prior pharmacokinetic parame-
ters (mean ± SD) were as follows: ke (0.70 ± 0.22 1/h);
V (9.03 ± 4.70 L/m2); kcp (0.080 ± 0.050 1/h); and kpc
(0.11 ± 0.0038 1/h). Clearance (CL) was calculated as
keV. Note that volume and clearance were always nor-
malized for body surface area.
Methotrexate dose individualization
The individualized methotrexate dose for each course was
determined as follows (Supplemental Figure 1):
Targeted dose mg=m2
 
¼ Infusion Length hð Þ  Predicted CL L=h=m2 
 Cpss lMð Þ= 2:2  1  fraction loading doseð Þð Þ
where the infusion length was 23 h (24–1 h loading dose
infusion), the fraction loading dose was 0.1 (or 10 %), and
the predicted clearance was defined as follows. For the
low-risk arm, the predicted clearance was assumed to be
equal to the clearance of the previous course of metho-
trexate. For the first 53 patients in the standard-/high-risk
arms, the predicted clearance was also assumed to be equal
to the clearance of the previous course of HDMTX.
However, due to the lower success of individualization by
this approach for patients on the standard-/high-risk arm
(see ‘‘Results’’), we investigated whether serum chemis-
tries (obtained within 24 h before the targeted course) or
patient demographics could help improve our ability to
predict the MTX clearance in the patients on the standard-/
high-risk arm and thus more accurately target individuals.
We considered serum chemistries as possible predictors of
MTX clearance because when MTX is infused over 24 h,
both renal and hepatic function play a role in clearance.
Approximately 40 % of HDMTX is cleared non-renally,
mostly via hepatic metabolism to 7-hydroxymethotrexate
[35], and both SGPT [36] and serum bilirubin [22] have
been associated with MTX clearance. Therefore, using the
data from the initial group of standard-/high-risk patients
on the protocol, we built a linear model with the previous
course MTX clearance, serum chemistries and demo-
graphics as potential predictors of the current course MTX
clearance, using stepwise linear regression (forward
selection followed by backward elimination) [37]. We
found a significant association between methotrexate
clearance and serum concentrations of creatinine, bilirubin
and SGPT (Supplemental Figure 2), and we estimated the
predicted clearance for patients in the standard-/high-risk
arms based on a linear function of the clearance of the
previous course of methotrexate along with current serum
concentrations of creatinine, bilirubin and SGPT (Supple-
mental Figure 1). If the clearance for the previous course of
methotrexate was [125 mL/min/m2, we used only the
previous clearance as the predicted clearance because it
was a more accurate predictor than the combination of
prior clearance and serum creatinine, bilirubin and SGPT
concentrations in such cases (Supplemental Figure 1).
Among patients on the low-risk arm, simulations did not
demonstrate an improvement in the prediction of clearance
if serum chemistries were incorporated.
We also simulated the methotrexate exposure (Cpss and
42 h methotrexate concentration) that would have been
achieved had patients received the conventional dose (i.e.,
2.5 g/m2 for low risk and 5 g/m2 for standard/high risk),
using the estimated methotrexate pharmacokinetic param-
eters for each course in each individual.
Targeting success
We measured targeting success by comparing the propor-
tion of courses that were successfully targeted (defined by
±20 % of the target Cpss [33 lM for low risk and 65 lM
for standard/high risk]) by pharmacokinetically based
doses vs fixed doses (simulated at 2.5 or 5.0 g/m2 for low
or standard/high risk, respectively) using the McNemar’s
V2 test. This ±20 % window was based on our prior intra-
course targeting study [13]. In addition, all targeted
patients had their doses adjusted to attempt to achieve the
target concentration, even if their predicted Cpss was
within 20 % of the target Cpss.
Toxicities
Toxicities during HDMTX consolidation were graded
using the NCI Common Toxicity Criteria version 2.0
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(http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/ctc.htm); we recorded any grade 3–4 toxicities
in the following categories: allergy/immunology, cardio-
vascular, constitutional symptoms, dermatology/skin,
gastrointestinal, hepatic, infection/febrile neutropenia,
metabolic/laboratory, musculoskeletal, neurology, pain,
pulmonary, renal/genitourinary. We determined whether
methotrexate exposure (Cpss or 42 h concentration),
delayed methotrexate excretion (42 h methotrexate con-
centration[1 lM), leucovorin dose, or success of targeting
methotrexate was associated with the incidence of grade 3




Of the 915 consolidation HDMTX courses delivered to the
233 patients on the low-risk arm, 754 courses in 220
patients were individualized based on the methotrexate
clearance from the previous course. The patient demo-
graphics are described in Supplemental Table 2. The
remaining doses were not pharmacokinetically based due
to various reasons, including no previous clearance data
being available, doses being lowered due to prior toxicities,
or other clinical issues such as unstable renal function. The
median dose administered for these pharmacokinetically
based courses was 2.8 g/m2, with a range of 0.9–5.3 g/m2,
and the median Cpss for the pharmacokinetically based
courses was 33 lM with a range from 15.6 to 92.3 lM.
This median Cpss observed with pharmacokinetically
based doses was 10 % higher than the simulated median
Cpss for patients on this study given a fixed dose of
2.5 g/m2 (p \ 0.001). Figure 1 shows the methotrexate
clearance subdivided by course. The overall population
clearance, inter-individual (IIV) and inter-occasion (IOV)
variability of the clearance were 117.9 ml/min/m2, 17.7
and 15.7 %, respectively.
For the low-risk arm, a higher proportion (69.5 %) of
pharmacokinetically based courses were within target
(defined as ±20 % of the Cpss of 33 lM) compared to that
estimated (60.3 %) had patients received a fixed dose of
2.5 g/m2 (p \ 2 9 10-4; Fig. 2).
There was substantial IIV and IOV in methotrexate
clearance for both window and consolidation therapy.
When subdivided by course, the IOV during the window
and first two consolidation courses was higher than that for
the later consolidation courses (15.8 vs. 11.3 %; p \ 0.03).
When comparing the change in clearance ([previous
clearance-current clearance]/current clearance) for phar-
macokinetically based courses 1 and 2 vs courses 3 and 4,
we observed more variability in the change in clearance for
the first two courses compared to the last two courses
([-23, 34 %] and [-20, 28 %] (10th, 90th percentile),
respectively; p \ 0.03). These differences in IOV over
time made it more difficult to accurately target courses 1
and 2 than the latter two consolidation courses. We
observed a higher proportion of courses with Cpss within
the target range for individualized doses in the latter two
consolidation courses: for consolidation 3 and 4: 9.6, 74.6,
and 15.8 % of courses were below target, within target and
above target, respectively; vs for consolidation 1 and 2:
15.5, 63.6, and 20.9 % of courses were below, within and
above target, respectively (p \ 0.001).
To assess whether individualizing doses minimized the
proportion of courses with extremes of plasma concentra-
tions of methotrexate, we compared the percent of courses
that yielded Cpss that were outside ±50 % of the target
(i.e., Cpss\16.5 lM or[49.5 lM for patients on the low-
risk arm, Fig. 2) for individualized courses vs that simu-
lated with conventional fixed dosing. Due to the higher
than expected clearance in patients in this arm, our simu-
lations show that the 2.5 g/m2 fixed dose actually would
have resulted in fewer courses with Cpss above 49.5 lM
compared to individualized doses (1.6 vs. 3.8 %;
p \ 0.005), while there was no difference in courses with
Cpss below 16.5 lM (0.5 vs. 0.3 %; p [ 0.1).
Finally, we observed a lower proportion of pharmacoki-
netically based courses with delayed excretion compared to
Fig. 1 Methotrexate clearance, MTX CL (ml/min/m2), by course and
risk arm. The horizontal line in each box represents the median, the
shaded boxes represent the quartiles, and the whiskers represent the
range observed in patients for each course. The solid horizontal line
across all courses represents the population clearance for all courses
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simulated fixed dose courses (7.4 vs. 8.9 %, respectively,
p \ 0.04).
Standard-/high-risk arm individualization
Of the 965 courses of consolidation HDMTX delivered to
252 patients on the standard-/high-risk arm, 97 courses in
53 patients had doses individualized based on the clearance
from the previous course; subsequently, for 627 courses in
224 patients, doses were individualized based on the
methotrexate clearance from the previous course along
with current serum creatinine, bilirubin, and SGPT. The
patient demographics are described in Supplemental
Table 2. The remaining courses were not pharmacokineti-
cally based due to various reasons including no previous
clearance being available, doses being lowered due to
toxicities, or other clinical issues, such as unstable renal
function. The median dose for courses individualized using
Fig. 2 Percentage of courses based on achieved MTX plasma steady-
state concentrations (Cpss) (individualized therapy) compared to the
percentage predicted based on conventional dosing (simulated for
fixed doses). The groups are defined as follows: Dark Blue Cpss
greater than 50 % below target Cpss, Light Blue Cpss between 20 and
50 % below target, Green Cpss within ±20 % of the target, Yellow
Cpss between 20 and 50 % above target, Red Cpss greater than 50 %
above target. *Significance (p \ 0.001) in the difference in the
proportion of courses between individualized therapy relative to
simulated fixed dose therapy (otherwise p [ 0.1). a Low-risk arm:
target concentration: 33 lM. b Standard-/high-risk arm: target
concentration: 65 lM
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only the previous clearance was 4.5 g/m2 (range 1.5–6.7 g/
m2), and for courses individualized using both the previous
clearance and serum chemistries was 4.6 g/m2 (range
2.9–8.6 g/m2). The median [10th–90th percentile] Cpss for
the courses targeted using only the previous clearance was
63 lM [34, 84 lM] while that for the courses individual-
ized, using both the previous clearance and serum chem-
istries was 63 lM [46, 83 lM]. This median Cpss observed
with pharmacokinetically based doses was 10 % lower than
the simulated median Cpss for patients on this study given
a fixed dose of 5 g/m2 (p \ 0.001). Figure 1 shows
the methotrexate clearance subdivided by course. The
overall population clearance, IIV, and IOV variability of
the clearance were 105.2 ml/min/m2, 17.5, and 16.9 %,
respectively.
As in the low-risk arm, the IOV for methotrexate
clearance for the window and first two consolidation
courses was higher than that for the later consolidation
courses (18.2 vs. 10.7 %; p \ 0.002). Again, the change in
clearance for individualized courses 1 and 2 displayed
more variability than for courses 3 and 4 ([-29, 35 %] and
[-21, 24 %] (10th, 90th percentile), respectively;
p \ 0.003). As with the low-risk arm, the high IOV in the
clearance for early courses made it more difficult to
accurately individualize the first two consolidation courses.
For the first 97 courses given to patients on the stan-
dard-/high-risk arm, when methotrexate was dosed based
only on the prior clearance, there was a trend for a lower
proportion of courses to achieve Cpss in the target range
compared to a conventional dose of 5 g/m2 (42.3 vs.
55.7 %; p = 0.087) and also compared to the subsequent
627 courses, when methotrexate was dosed based on the
previous clearance plus the current serum chemistries (42.3
vs. 62.8 %, p \ 0.001). Thus, our final approach was to
base doses for the standard-/high-risk group on both the
previous clearance and the current serum chemistries. In
the final analysis, there was not a significant difference in
the proportion of pharmacokinetically based courses with
Cpss that were within target (n = 627) compared to that
of conventional dosing of 5 g/m2 (62.8 vs. 60.9 %,
respectively; p = 0.43; Fig. 2). However, there was a
significantly lower proportion of courses with Cpss above
the targeted range with individualized dosing compared to
that predicted with conventional dosing (17.2 vs. 30.5 %,
respectively; p \ 0.001; Fig. 2). Again, due to the larger
IOV in methotrexate PK for the early compared to later
courses, we observed a trend toward (p = 0.12) better
success in achieving target Cpss with individualized doses
in the latter two consolidation courses (consolidation 3
and 4: 17.8, 65.0, and 17.2 % below, within and above
target, respectively) compared to consolidation 1 and 2
(22.7, 60.1, and 17.3 % below, within and above target,
respectively).
Next, to assess how well the individualization avoided
extreme plasma concentrations of MTX, we compared how
many courses yielded Cpss outside ±50 % of the target
(i.e., Cpss \32.5 or [97.5 lM). By using pharmacokinet-
ically based doses, the proportion of courses with extre-
mely high Cpss was lower than that simulated with a fixed
dose (1.3 vs. 7.3 %; p \ 10-8, Fig. 2), while there was no
difference in the frequency of courses with extremely low
Cpss (0.3 vs 0.0 %; p = 0.48, Fig. 2).
Finally, we observed a lower proportion of courses with
delayed excretion when individualized dosing was used
compared to what we would have observed had we given
fixed doses (14.7 vs. 19.8 %, respectively, p \ 0.001).
Toxicity
The overall rate of any grade 3–4 toxicity in this study was
low (160 events from 1,880 methotrexate consolidation
courses or 8.5 % of courses) (Table 1). Infection/febrile
neutropenia and gastrointestinal toxicities were the most
common events, occurring in 5.2 and 3.0 % of courses,
respectively. As expected based on the protocol guidelines
(Supplemental Table 1), there was a 4.3-fold increase in
the total leucovorin dose in patients with delayed excretion
for the low-risk arm (p \ 0.001) and a 2.2-fold increase for
the standard- and high-risk arms (p \ 0.001).
We investigated the relationship between methotrexate
Cpss, methotrexate 42-h concentration, targeting success
(Cpss ±20 % of target), leucovorin dose, methotrexate
Table 1 Grade 3 or 4 toxicities during consolidation therapy
LR individualized LR not individualized S/HR individualized S/HR not individualized
Methotrexate courses (n) 754 161 627 338
Patients (n) 220 101 224 176
Courses with infection/febrile neutropenia (n) 33 10 29 26
Course with gastrointestinal toxicities (n) 13 3 19 22
Courses with any grade 3 or 4 toxicity [n (%)] 52 (6.9) 14 (8.7) 50 (8.0) 44 (13.0)
LR Low-risk therapy arm, S/HR standard-/high-risk therapy arm, Individualized courses for which the methotrexate dose was adjusted based on
the prior course’s pharmacokinetic parameters, Not Individualized courses for which the methotrexate was dosed conventionally based on body
size
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delayed excretion, and risk of gastrointestinal toxicity. In
the low-risk arm, higher methotrexate Cpss corresponded
to a higher odds (5 % higher for every 1 lM increase in the
Cpss) of having a grade 3 or greater gastrointestinal tox-
icity (OR 1.05; 95 % CI 1.01–1.09, p = 0.021) (Supple-
mental Table 3). In the standard-/high-risk arm,
methotrexate delayed excretion was associated with gas-
trointestinal toxicities (OR 3.02; 95 % CI 1.45–6.32,
p = 0.003). No other measures of methotrexate exposure
or targeting success related significantly to toxicity
(p [ 0.05 in all cases).
Of a total of 1,880 consolidation courses in 484 patients
receiving HDMTX, severe delayed excretion (requiring
glucarpidase) occurred for a single course in each of only 4
patients (0.8 % of patients and 0.21 % of courses). All 4 of
these patients received targeted dosing on the standard-/
high-risk arm and had a large (24–71 %) decrease in their
MTX clearance between their previous course of MTX
(used for targeting) and the course with severe delayed
excretion. Patients requiring glucarpidase were eligible to
be targeted with future courses. MTX concentrations used
to target were obtained prior to administration of glu-
carpidase; therefore, falsely elevated concentrations due to
the glucarpidase were not an issue.
Discussion
HDMTX is an important chemotherapeutic agent that
contributes to the high cure rate of pediatric ALL [6, 7, 38].
Higher plasma methotrexate concentrations following
HDMTX have been associated with a lower risk of relapse
[10, 11]; however, high concentrations may lead to delayed
excretion, increased toxicity and delays in receiving sub-
sequent courses of chemotherapy [22]. In a previous study,
we have shown that adjusting the dose of methotrexate
during the 24-h infusion, to account for inter-individual
differences in drug clearance and to achieve a target Cpss,
improved the outcome in children with B-lineage leukemia
[10, 13, 29]. Other studies have retrospectively investigated
therapeutic drug-monitoring approaches to predict MTX
concentrations after a dose to help determine appropriate
leucovorin rescue [31]. In the current study, we tested
whether we could successfully individualize doses of
HDMTX based on clearance estimates from the prior
course of MTX for each child; this method relies on the
assumption that IOV is low enough that prior clearance
accurately reflects current clearance. However, we
observed high IOV, particularly for the first and second
course of HDMTX. Recognizing this large IOV, we mod-
ified our targeting strategy in the standard-/high-risk arm to
include not only prior pharmacokinetic parameters, but also
serum chemistries (drawn within 24 h of each planned
HDMTX course) as a surrogate for changing methotrexate
clearance. Simulations showed that serum chemistries
would not have improved targeting in the low-risk arm.
Targeting doses based on the prior course’s pharmaco-
kinetic parameters was moderately successful. For the low-
risk arm, more courses had Cpss that were within target
(70 %) compared to simulated conventional dosing (60 %;
p \ 0.001). The median targeted dose was 11 % higher
than the conventional 2.5 g/m2 dose without an increase in
delayed excretion. For the standard-/high-risk arm, even
after incorporation of current serum chemistries, we were
not successful in improving the percentage of courses with
Cpss in the target range (±20 %) over that achieved with
conventional dosing. We attribute this finding to the higher
IOV in clearance relative to the low-risk arm, which could
be exacerbated in patients on the standard-/high-risk arm
because clearance of higher doses of MTX is more sus-
ceptible to transient insults (e.g., changes in hydration,
drug interactions). Nonetheless, individualized dosing
decreased the frequency of both extreme Cpss and of
delayed excretion in patients on the standard-/high-risk
arm. For courses given to patients on the standard-/high-
risk arm, only 1 % of those that received individualized
dosing had Cpss [50 % above target compared to 7 % of
courses with simulated conventional dosing (p \ 0.001).
This translated into a lower proportion of individualized
courses with delayed excretion.
Gastrointestinal toxicities are known side effects of
HDMTX. In our prior study comparing conventional versus
individualized chemotherapy, with a Cpss of only 20 lM,
there was no difference in toxicity between the two groups
[13]. In the current study, using much higher target con-
centrations of 33 and 65 lM, minimal toxicity was noted
following HDMTX. Overall, 5.2 % of courses were fol-
lowed by grade 3–4 infection/febrile neutropenia and
3.0 % was followed by grade 3–4 gastrointestinal toxici-
ties. These toxicity rates were low compared to other
studies. In the POG9404 study, patients that received
HDMTX (5 g/m2 over 24 h) had a 17.8 % incidence of
mucositis and 66.2 % incidence of infection [7]. For
patients on the LAL-SHOP 99 and 2005 protocols receiv-
ing HDMTX of 3 or 5 g/m2, there was an 11 % incidence
of mucositis [39]. D’Angelo and colleagues [40] reviewed
patients enrolled on AIEOP-ALL studies 91, 95 and 00 and
reported that 68.2 % of patients developed grade 3–4
hematologic and non-hematologic toxicity combined after
HDMTX doses of 2 or 5 g/m2. The BFM study NHL-
BFM95 reported incidences of 36 % for grade 3 and 43 %
for grade 4 mucositis in patients with B-cell neoplasms
receiving 5 g/m2 over 24 h; perhaps this high frequency is
partly attributed to only three doses of leucovorin being
administered after HDMTX compared to our 5 doses [41].
Leucovorin dose was not a risk factor for toxicity in either
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our LR or S/HR arms, despite being significantly higher in
those with elevated 42-h concentrations. Thus, our data
suggest that the algorithms we used (Supplemental
Table 1) for adjusting leucovorin doses based on plasma
methotrexate concentrations, combined with our targeting
strategy, were effective in producing a low frequency of
adverse effects. It should also be noted that the relapse rate
on the Total XV protocol was very low [1].
Renal excretion plays a major role in methotrexate
elimination, and methotrexate itself can cause acute
nephrotoxicity. Close monitoring of patients receiving
methotrexate is imperative. At St. Jude, close monitoring of
fluid status, urine output, urine pH, laboratory values,
methotrexate concentrations [22, 23, 42] and drug inter-
actions (through review of the patient’s electronic record)
in order to prevent delayed excretion and toxicity are
performed with each course of HDMTX. Close monitoring
allows early intervention (e.g., increasing fluid hydration,
discontinuing interacting drugs) and potentially reduces
adverse effects. Using prior information about a patient’s
MTX clearance to individualize a patient’s dosage of
HDMTX is an added way to potentially reduce adverse
effects when within-course dose adjustment is not feasible.
However, we acknowledge that targeting doses based on
clearance did not prevent all cases of severe nephrotoxi-
city. For those patients who do experience nephrotoxicity
during or after a course of HDMTX, it is likely that intra-
course clearance estimates with intra-course dose adjust-
ments, as we previously described [13], would be more
likely to prevent recurrence of severe nephrotoxicity than
between-course adjustments.
Our current clinical approach to administering HDMTX
in ALL is as follows. Because with the lower dose
(*2.5 g/m2), the proportion of courses with delayed
excretion was only modestly reduced (8.9 vs. 7.4 %) by
targeting, we generally do not pharmacokinetically adjust
doses of this lower dose of HDMTX unless the patient
displays unstable or poor renal function. For patients
receiving the equivalent of 5 g/m2, we adjust doses based
on the pharmacokinetics of the prior course in most
patients, because in the current study, we showed that
individualizing doses reduced both the frequency of
extremely high Cpss (1.3 vs. 7.3 %) and the frequency of
delayed excretion (14.7 vs. 19.8 %). In the relatively rare
patients with unstable clearance or renal function, we
measure plasma concentrations early during the infusion as
we described previously [13, 29] and adjust doses during
the infusion to achieve the desired Cpss.
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